Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series.
CGRP
Migraine
Monoclonal antibodies
Non-responders
Real-world-data
Switchers
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
28 Apr 2023
28 Apr 2023
Historique:
received:
12
09
2022
accepted:
10
04
2023
medline:
1
5
2023
pubmed:
29
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Assessement of the responder and non-responder rate to consecutive monoclonal CGRP-antibody (CGRP-mAb) treatment, the presence of side effects, analysis of predictors of response and loss-of-effectiveness evaluation over time. We conducted a retrospective analysis including 171 patients with episodic (EM) or chronic migraine (CM), who received one, two or three different CGRP-mAbs. Non-response was defined as ≤ 50% reduction of monthly migraine days (MMDs) in EM and ≤ 30% reduction of MMDs in CM after 3 months of treatment. 123 (71.9%) responded to the first mAb. Side effects led to treatment discontinuation in 9 (5.3%) patients. Of the 26 patients who did not respond to the first mAb or experienced a loss of efficacy over time, 11 (42.3%) responded to the second and two (28.6%) of 7 to the third monoclonal antibody. Poor response to therapy was associated with a higher monthly migraine frequency (p = 0.028), a higher number of prior preventive migraine therapies (p = 0.011) and medication overuse (p = 0.022). Our findings support mAb-class switch in non-responders or in patients experiencing a loss of effectiveness. The use of a third CGRP-mAb could be beneficial for some patients.
Identifiants
pubmed: 37118682
doi: 10.1186/s12883-023-03203-9
pii: 10.1186/s12883-023-03203-9
pmc: PMC10142255
doi:
Substances chimiques
Antibodies, Monoclonal
0
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174Informations de copyright
© 2023. The Author(s).
Références
J Headache Pain. 2022 Jun 11;23(1):67
pubmed: 35690723
Ann Neurol. 1993 Jan;33(1):48-56
pubmed: 8388188
Headache. 2020 Feb;60(2):469-470
pubmed: 31872439
J Headache Pain. 2020 Jul 3;21(1):84
pubmed: 32620151
Cephalalgia. 2022 Apr;42(4-5):291-301
pubmed: 34644203
Cephalalgia. 2021 Apr;41(5):499-514
pubmed: 33626922
Headache. 2019 Jan;59(1):1-18
pubmed: 30536394
JAMA Neurol. 2018 Sep 1;75(9):1080-1088
pubmed: 29813147
Lancet Neurol. 2017 Jun;16(6):425-434
pubmed: 28460892
Adv Ther. 2021 Nov;38(11):5465-5483
pubmed: 34542830
J Headache Pain. 2020 Jun 1;21(1):61
pubmed: 32487102
JAMA. 2018 May 15;319(19):1999-2008
pubmed: 29800211
Neurology. 2000 Sep 12;55(5):629-35
pubmed: 10980724
Headache. 2021 Jul;61(7):1021-1039
pubmed: 34160823
Lancet. 2019 Sep 21;394(10203):1030-1040
pubmed: 31427046
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Cephalalgia. 2021 Oct;41(11-12):1222-1239
pubmed: 34130525
Headache. 2022 Jan;62(1):78-88
pubmed: 34807454
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Lancet. 2018 Nov 24;392(10161):2280-2287
pubmed: 30360965
J Neurol Sci. 2013 Aug 15;331(1-2):48-56
pubmed: 23790235
Neurology. 2018 Dec 11;91(24):e2211-e2221
pubmed: 30446596
CNS Drugs. 2021 Aug;35(8):805-820
pubmed: 34272688
Cephalalgia. 2020 Nov;40(13):1511-1522
pubmed: 32791922
Cephalalgia. 2019 Sep;39(10):1284-1297
pubmed: 30917684
Cephalalgia. 2020 Mar;40(3):241-254
pubmed: 32075406
Ann Neurol. 1988 Feb;23(2):193-6
pubmed: 2454066
Nature. 1983 Jul 14-20;304(5922):129-35
pubmed: 6346105
Cephalalgia. 2022 Feb;42(2):108-118
pubmed: 34743579
N Engl J Med. 2017 Nov 30;377(22):2113-2122
pubmed: 29171818
Neurology. 2020 Mar 31;94(13):e1365-e1377
pubmed: 32209650
Neurology. 2020 Nov 3;95(18):e2487-e2499
pubmed: 32913018
Nat Rev Neurol. 2012 Feb 14;8(3):162-71
pubmed: 22331030